Taysha Gene Therapies, Inc. TSHA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$129.88M-19.2% | -$109M-9.1% | -$99.93M-7.8% | -$92.72M-6.9% | -$86.77M+2.8% | ||
| $1.09M+1.1% | $1.08M-0.5% | $1.09M-8.4% | $1.19M0.0% | $1.19M-3.4% | ||
| $15.55M+16.9% | $13.3M+2.4% | $12.99M-0.6% | $13.06M-1.1% | $13.2M+0.7% | ||
| $213K+239% | -$153K-133% | $469K+134% | -$1.36M+77.2% | -$5.98M-105% | ||
| —— | —— | —— | —— | $152K+173% | ||
| -$328K-10.8% | -$296K+11.9% | -$336K+65.9% | -$985K-32.4% | -$744K+4.1% | ||
| —— | -$9.77M-54.9% | -$6.31M+22.1% | -$8.1M-12.1% | -$7.22M+13.3% | ||
| $1.31M-4.0% | $1.36M+7.9% | $1.26M+1.2% | $1.25M+1.1% | $1.23M+1.2% | ||
| -$111.95M-20.3% | -$93.09M-9.9% | -$84.68M-3.1% | -$82.13M+1.6% | -$83.45M-2.7% | ||
| $384K-48.0% | $738K+51.2% | $488K+17.6% | $415K-32.4% | $614K+63.3% | ||
| —— | -$134K-0.2% | -$133.75K-74.8% | -$76.5K-402% | -$15.25K-38.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$607K-61.4% | ||
| $1.66M+36.1% | $1.22M— | —— | —— | —— | ||
| -$238K+29.4% | -$337K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $275.35M+0.3% | $274.59M+22.0% | $225.03M+1.0% | $222.83M+189% | $77.01M0.0% | ||
| $175.56M-10.6% | $196.31M+26.6% | $155.07M+10.8% | $140.02M+1,995% | -$7.39M-50.6% | ||
| $5.55M+2.8% | $5.4M+2.8% | $5.25M+0.7% | $5.21M-0.6% | $5.25M-0.7% | ||
| $1.09M+1.1% | $1.08M-0.5% | $1.09M-8.4% | $1.19M0.0% | $1.19M-3.4% | ||
| $3.27M-48.1% | $6.29M— | —— | —— | —— | ||
| —— | —— | —— | —— | $152K+173% | ||
| $608K-26.9% | $832K+892% | -$105K-194% | $112K+219% | -$94K+84.3% | ||
| $1.31M-4.0% | $1.36M+7.9% | $1.26M+1.2% | $1.25M+1.1% | $1.23M+1.2% | ||
| -$328K-10.8% | -$296K+11.9% | -$336K+65.9% | -$985K-32.4% | -$744K+4.1% | ||
| —— | -$134K-0.2% | -$133.75K-74.8% | -$76.5K-402% | -$15.25K-38.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $48.44M— | —— | —— | —— | ||
| -$238K+29.4% | -$337K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $434K+655% | $57.5K+25.0% | ||
| —— | $1.2M+216% | $380K— | —— | —— | ||
| —— | -$9.77M-54.9% | -$6.31M+22.1% | -$8.1M-12.1% | -$7.22M+13.3% | ||
| —— | $225K— | —— | —— | —— | ||
| —— | $2.37M— | —— | —— | —— | ||
| —— | $1.64M— | —— | —— | —— | ||
| -$112.33M-19.7% | -$93.83M-10.2% | -$85.16M-3.2% | -$82.54M+1.8% | -$84.06M-3.0% | ||
| -$112.33M-19.7% | -$93.83M-10.2% | -$85.16M-3.2% | -$82.54M+1.8% | -$84.06M-3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Taysha Gene Therapies, Inc. generate?
- Taysha Gene Therapies, Inc. (TSHA) generated -$111.9M in operating cash flow over the trailing twelve months.
- What is Taysha Gene Therapies, Inc.'s free cash flow?
- After $384.0K of capital expenditures, Taysha Gene Therapies, Inc.'s free cash flow was -$112.3M over the trailing twelve months, down 33.6% year over year.
- Where does Taysha Gene Therapies, Inc.'s cash flow data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
